If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retevmo™ (selpercatinib) capsules
40 mg, 80 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
RETEVMO™ (selpercatinib): Dosing Considerations
Selpercatinib may be taken with or without food unless coadministered with a proton pump inhibitor.
Selpercatinib doses should be separated by approximately 12 hours.
A missed dose of selpercatinib should not be made up within 6 hours of the next scheduled dose.
Selpercatinib capsules should be swallowed whole and should not be opened, crushed, or chewed.1
Lilly currently has no information available on the opening of the capsules and administering the content in liquids or food for administration (such as mixing in applesauce) or administration through a G-tube.
If vomiting occurs after taking a dose of selpercatinib, do not administer an additional dose. Take the next dose at the scheduled time.1
Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. The recommended dose of selpercatinib based on actual body weight is detailed in Table 1.1
Table 1. Recommended Selpercatinib Dosage1
|
Patient Weighta |
Recommended Dosage |
|
<50 kg |
120 mg orally twice daily |
|
≥50 kg |
160 mg orally twice daily |
a Based on actual patient weight.
Enclosed Prescribing Information
RETEVMO™ (selpercatinib) capsules, for oral use, Lilly
1. Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
G-tube = gastrostomy tube
Lilly = Eli Lilly and Company
Date of Last Review: May 22, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
